Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Rating of “Hold” by Brokerages

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $10.28.

MRVI has been the topic of a number of recent analyst reports. Wells Fargo & Company began coverage on shares of Maravai LifeSciences in a report on Tuesday, August 27th. They set an “overweight” rating and a $10.00 target price on the stock. The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their target price for the company from $7.00 to $4.25 in a report on Thursday, December 5th. Royal Bank of Canada reduced their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Wolfe Research started coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th.

Insider Transactions at Maravai LifeSciences

In other Maravai LifeSciences news, insider Carl Hull bought 175,000 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were purchased at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the transaction, the insider now directly owns 175,000 shares in the company, valued at approximately $987,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several institutional investors have recently made changes to their positions in MRVI. Creative Planning raised its holdings in Maravai LifeSciences by 4.4% in the 3rd quarter. Creative Planning now owns 44,943 shares of the company’s stock valued at $373,000 after acquiring an additional 1,881 shares in the last quarter. Kornitzer Capital Management Inc. KS increased its holdings in Maravai LifeSciences by 0.7% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 519,890 shares of the company’s stock valued at $4,320,000 after buying an additional 3,725 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Maravai LifeSciences in the 2nd quarter valued at approximately $32,000. Liontrust Investment Partners LLP lifted its holdings in shares of Maravai LifeSciences by 14.7% during the 2nd quarter. Liontrust Investment Partners LLP now owns 43,845 shares of the company’s stock worth $314,000 after acquiring an additional 5,628 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Maravai LifeSciences in the third quarter valued at approximately $47,000. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Stock Down 1.1 %

MRVI stock opened at $5.37 on Tuesday. Maravai LifeSciences has a twelve month low of $4.28 and a twelve month high of $11.56. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -3.27 and a beta of -0.08. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The business has a 50 day moving average price of $6.30 and a two-hundred day moving average price of $7.63.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.